<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629041</url>
  </required_header>
  <id_info>
    <org_study_id>Innoture/NW-01</org_study_id>
    <nct_id>NCT03629041</nct_id>
  </id_info>
  <brief_title>A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity</brief_title>
  <official_title>A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innoture Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innoture Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To look at the effect on patient perceived pain resulting from infiltration injection with
      local anaesthetic in a dental syringe with prior application of topical anaesthetic to the
      oral mucosa on a microneedle patch compared to a patch with no microneedles. To look at the
      safety of the patches when applied to the oral mucosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, 2 treatment, double blind design, with respect to the clinical assessor
      and subject, split mouth, crossover design with a negative control (patch with no
      microneedles).

      Potential participants will be invited to attend a screening visit. At this visit
      participants will be asked to read and sign a Participant Information Sheet and Consent Form
      prior to any study procedures being performed. They will be given ample time to decide if
      they wish to participate in the study.

      A dentally qualified clinician will record the participant's demographics, medical history,
      current/concomitant medications, perform an oral soft tissue examination and ensure the
      participant fulfils the inclusion and exclusion criteria for the study. Two areas of the
      mouth will be identified for assessment during the study. The areas of the mouth will be
      identified as S1 or S2. Site S1 will be left or right palatal mucosa adjacent to the premolar
      area and S2 will be left or right upper buccal mucosa adjacent to the upper lateral incisor
      area.

      Participants who successfully fulfil all the necessary entrance criteria will be provided
      with training by study staff on how to use a VAS record sheet and randomised on to the study
      to receive treatment combination A or B at in a random order according to a predetermined
      randomisation schedule supplied by the study statistician. The screening visit and first
      treatment visit will occur at the same visit. The treatment possibilities are outlined below:

      Treatment A The application of a 5% topical lidocaine gel to one of the identified areas
      within the participants mouth using a microneedle patch. The microneedle patch will be
      applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration
      with local anaesthetic to one of the identified areas within the participants mouth.

      Treatment B The application of a 5% topical lidocaine gel to one of the identified sites
      within the participants mouth using a patch with no microneedles. The patch with no
      microneedles will be applied to the oral mucosa of the identified site for 3 minutes,
      followed by infiltration with local anaesthetic to one of the identified areas within the
      participants mouth.

      The chosen sites will be: S1; left and right palatal mucosa adjacent to the premolar area or
      S2; left and right upper buccal mucosa adjacent to the upper lateral incisor area. Each
      participant at the first visit will have either S1 or S2 sites allocated for treatment. For
      example, Treatment A will be allocated to S1 left side and Treatment B to S1 right side or
      vice versa. At the second visit, 2 weeks (+/- 3 days) after the first visit, Treatment B will
      be allocated to S2 left side and Treatment A to S2 right side. Both sides of the mouth for S1
      or S2 will be treated at the same. After each treatment participants will be asked to make
      pain assessments relating to needle insertion into the oral mucosa and the giving of the
      local infiltration anaesthetic.

      It is envisaged that a sufficient number of potential participants will be screened in order
      to randomise 16 onto the study.

      Assessment methods: Pain assessments will be performed after application of the topical
      anaesthetic for 3 minutes. Each test will be performed sequentially i.e. 3 separate needle
      insertions, with pain assessments recorded by the participant using a Visual Analogue Scale
      (VAS) and a verbal pain grading after each test. The level of pain at S1 or S2 will be
      assessed as follows:

      Test I. A short dental needle, mounted on a dental syringe containing a cartridge of 2%
      lidocaine hydrochloride and 1:80,000 adrenaline, will be used to penetrate the oral mucosa at
      the treated site and the patient asked to score the pain using a VAS rating scale and by
      verbal grading of zero, mild, moderate or severe.

      Test 2. The same needle will be inserted through the oral mucosa and down to contact bone.
      Pain will be assessed as in Test 1.

      Test 3. The same needle will be again inserted through the oral mucosa and the cartridge of
      local anaesthetic will be injected into the site. Pain will be again assessed as in Test I.

      Following enrolment on to the study, participants will be given written and verbal
      instructions on the VAS and how to complete it.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Actual">August 22, 2018</completion_date>
  <primary_completion_date type="Actual">August 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS in Healthy Participants, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.</measure>
    <time_frame>Following 3 minutes of application of topical anaesthetic using a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
    <description>Pain levels were recorded using a visual analogue scale (VAS). When responding to the VAS item, subjects were required to indicate their level of pain by indicating a position along a continuous line between two end-points of no pain (0) and worst pain imaginable (100). The lower the score the better the outcome. The topical lidocaine was applied either with a microneedle patch or a patch with no microneedles for 3 minutes. Immediately afterwards three tests were performed: Test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site; test 2, the same needle was inserted through the oral mucosa and down to contact bone; test 3, the same needle was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel is Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 1</measure>
    <time_frame>Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
    <description>Pain levels will be recorded using a Verbal Pain Grading. For the verbal pain grading, subjects are asked to score either zero, mild, moderate or severe. In test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 2</measure>
    <time_frame>Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
    <description>Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 2, the same needle as test 1 was inserted through the oral mucosa and down to contact bone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 3</measure>
    <time_frame>Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
    <description>Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 3, the same needle as test 1 and test 2 was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events in Healthy Participants When a Proprietary Topical 5% Lidocaine Dental Gel Was Applied to the Oral Mucosa With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.</measure>
    <time_frame>Events were collected from the time of informed consent until end of treatment or when an ongoing AE had resolved whichever was latest, unless the PI &amp; the Innoture contact from the clinical investigation plan agreed that no further follow up was needed.</time_frame>
    <description>Adverse events were recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Topical Anaesthesia</condition>
  <arm_group>
    <arm_group_label>Treatment A - Microneedle patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B - Patch with no microneedles</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedle Patch</intervention_name>
    <description>At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.</description>
    <arm_group_label>Treatment A - Microneedle patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patch with no microneedles</intervention_name>
    <description>At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.</description>
    <arm_group_label>Treatment B - Patch with no microneedles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. be aged 18 years and over, of either gender and in good health;

          2. be willing and physically able to carry out all study procedures;

          3. be willing and able to give Informed Consent and provide details of any medical
             history;

          4. be available for all of the study dates

          5. have a good standard of oral hygiene and gingival health

          6. must have 1 premolar or canine in each quadrant that has no/minimal restorations

        Exclusion Criteria:

          1. presence of soft tissue oral pathology;

          2. presence of advanced periodontal disease;

          3. Individuals with any serious health conditions, that would preclude participation, in
             the professional judgement of the Study Dentist;

          4. individuals with known allergies or sensitivities to local anaesthetics

          5. have participated in another clinical trial in the last 30 days

          6. in the opinion of the investigator unable to comply fully with the trial requirements.

          7. the subject is an employee of the Sponsor or the site conducting the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola X West</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bristol Dental School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rhiwbina Dental Surgery</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 6HB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>October 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2019</results_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03629041/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were healthy volunteers who have their regular dental care at Rhiwbina Dental Surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group 1</title>
          <description>At visit 1 the left upper palatal area was treated with lidocaine on a microneedle patch for three minutes and the right upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days after visit 1) the left upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group 2</title>
          <description>At visit 1 the left upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes and the right upper palatal area was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days from visit 1) the left upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Group 3</title>
          <description>At visit 1 the left upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days from visit 1) the left upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes and the right upper palatal area was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Group 4</title>
          <description>At visit 1 the left upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days after visit 1) the left upper palatal area was treated with lidocaine on a microneedle patch for three minutes and the right upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Visit 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Visit 2 (2 Weeks Â± 3 Days From Visit 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" lower_limit="18.9" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VAS in Healthy Participants, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.</title>
        <description>Pain levels were recorded using a visual analogue scale (VAS). When responding to the VAS item, subjects were required to indicate their level of pain by indicating a position along a continuous line between two end-points of no pain (0) and worst pain imaginable (100). The lower the score the better the outcome. The topical lidocaine was applied either with a microneedle patch or a patch with no microneedles for 3 minutes. Immediately afterwards three tests were performed: Test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site; test 2, the same needle was inserted through the oral mucosa and down to contact bone; test 3, the same needle was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.</description>
        <time_frame>Following 3 minutes of application of topical anaesthetic using a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Microneedle Patch, Palatal</title>
            <description>The application of a 5% topical lidocaine gel to the palatal mucosa within the participants mouth using a microneedle patch. The microneedle patch was applied to the palatal mucosa for 3 minutes, followed by infiltration with local anaesthetic to the palatal mucosa within the participants mouth.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - Patch With no Microneedles, Palatal</title>
            <description>The application of a 5% topical lidocaine gel to the palatal mucosa sites within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied to the palatal mucosa for 3 minutes, followed by infiltration with local anaesthetic to the palatal mucosa within the participants mouth.</description>
          </group>
          <group group_id="O3">
            <title>Treatment A - Microneedle Patch, Buccal</title>
            <description>The application of a 5% topical lidocaine gel to the buccal mucosa within the participants mouth using a microneedle patch. The microneedle patch was applied to the buccal mucosa for 3 minutes, followed by infiltration with local anaesthetic to the buccal mucosa within the participants mouth.</description>
          </group>
          <group group_id="O4">
            <title>Treatment B - Patch With no Microneedles, Buccal</title>
            <description>The application of a 5% topical lidocaine gel to the buccal mucosa sites within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied to the buccal mucosa for 3 minutes, followed by infiltration with local anaesthetic to the buccal mucosa within the participants mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS in Healthy Participants, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.</title>
          <description>Pain levels were recorded using a visual analogue scale (VAS). When responding to the VAS item, subjects were required to indicate their level of pain by indicating a position along a continuous line between two end-points of no pain (0) and worst pain imaginable (100). The lower the score the better the outcome. The topical lidocaine was applied either with a microneedle patch or a patch with no microneedles for 3 minutes. Immediately afterwards three tests were performed: Test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site; test 2, the same needle was inserted through the oral mucosa and down to contact bone; test 3, the same needle was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS scores, test 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="5.8"/>
                    <measurement group_id="O2" value="12.3" spread="11.6"/>
                    <measurement group_id="O3" value="0.7" spread="1.0"/>
                    <measurement group_id="O4" value="4.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS scores, test 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="11.3"/>
                    <measurement group_id="O2" value="18.7" spread="12.4"/>
                    <measurement group_id="O3" value="2.8" spread="4.0"/>
                    <measurement group_id="O4" value="6.9" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS scores, test 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="20.1"/>
                    <measurement group_id="O2" value="39.5" spread="25.1"/>
                    <measurement group_id="O3" value="18.3" spread="17.5"/>
                    <measurement group_id="O4" value="30.6" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel is Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 1</title>
        <description>Pain levels will be recorded using a Verbal Pain Grading. For the verbal pain grading, subjects are asked to score either zero, mild, moderate or severe. In test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site.</description>
        <time_frame>Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Microneedle Patch, Palatal</title>
            <description>5% topical lidocaine gel was applied to the upper palatal area within the participants mouth using a microneedle patch. The microneedle patch was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - Patch With no Microneedles, Palatal</title>
            <description>5% topical lidocaine gel was applied to the upper palatal area within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment A - Microneedle Patch, Buccal</title>
            <description>5% topical lidocaine gel was applied to the upper anterior buccal sulcus within the participants mouth using a microneedle patch. The microneedle patch was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O4">
            <title>Treatment B - Patch With no Microneedles, Buccal</title>
            <description>5% topical lidocaine gel was applied to the upper anterior buccal sulcus within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel is Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 1</title>
          <description>Pain levels will be recorded using a Verbal Pain Grading. For the verbal pain grading, subjects are asked to score either zero, mild, moderate or severe. In test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Verbal Pain Grading, Test 1- Zero</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 1 - Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 1 - Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 1 - Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events in Healthy Participants When a Proprietary Topical 5% Lidocaine Dental Gel Was Applied to the Oral Mucosa With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.</title>
        <description>Adverse events were recorded</description>
        <time_frame>Events were collected from the time of informed consent until end of treatment or when an ongoing AE had resolved whichever was latest, unless the PI &amp; the Innoture contact from the clinical investigation plan agreed that no further follow up was needed.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>At visit 1 the left upper palatal area was treated with lidocaine on a microneedle patch for three minutes and the right upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days after visit 1) the left upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group 2</title>
            <description>At visit 1 the left upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes and the right upper palatal area was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days from visit 1) the left upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Group 3</title>
            <description>At visit 1 the left upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days from visit 1) the left upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes and the right upper palatal area was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
          </group>
          <group group_id="O4">
            <title>Treatment Group 4</title>
            <description>At visit 1 the left upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days after visit 1) the left upper palatal area was treated with lidocaine on a microneedle patch for three minutes and the right upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events in Healthy Participants When a Proprietary Topical 5% Lidocaine Dental Gel Was Applied to the Oral Mucosa With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.</title>
          <description>Adverse events were recorded</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 2</title>
        <description>Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 2, the same needle as test 1 was inserted through the oral mucosa and down to contact bone.</description>
        <time_frame>Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Microneedle Patch, Palatal</title>
            <description>5% topical lidocaine gel was applied to the upper palatal area within the participants mouth using a microneedle patch. The microneedle patch was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - Patch With no Microneedles, Palatal</title>
            <description>5% topical lidocaine gel was applied to the upper palatal area within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment A - Microneedle Patch, Buccal</title>
            <description>5% topical lidocaine gel was applied to the upper anterior buccal sulcus within the participants mouth using a microneedle patch. The microneedle patch was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O4">
            <title>Treatment B - Patch With no Microneedles, Buccal</title>
            <description>5% topical lidocaine gel was applied to the upper anterior buccal sulcus within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 2</title>
          <description>Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 2, the same needle as test 1 was inserted through the oral mucosa and down to contact bone.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Verbal Pain Grading, Test 2 - Zero</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 2 - Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 2 - Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 2 - Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 3</title>
        <description>Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 3, the same needle as test 1 and test 2 was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.</description>
        <time_frame>Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Microneedle Patch, Palatal</title>
            <description>5% topical lidocaine gel was applied to the upper palatal area within the participants mouth using a microneedle patch. The microneedle patch was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - Patch With no Microneedles, Palatal</title>
            <description>5% topical lidocaine gel was applied to the upper palatal area within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment A - Microneedle Patch, Buccal</title>
            <description>5% topical lidocaine gel was applied to the upper anterior buccal sulcus within the participants mouth using a microneedle patch. The microneedle patch was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
          <group group_id="O4">
            <title>Treatment B - Patch With no Microneedles, Buccal</title>
            <description>5% topical lidocaine gel was applied to the upper anterior buccal sulcus within the participants mouth using a patch with no microneedles. The patch with no microneedles was applied for 3 minutes and then removed, followed by tests 1, 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 3</title>
          <description>Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 3, the same needle as test 1 and test 2 was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Verbal Pain Grading, Test 3 - Zero</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 3 - Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 3 - Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Verbal Pain Grading, Test 3 - Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of informed consent until end of treatment or when an ongoing AE had resolved whichever was latest, unless the PI and the Innoture contact named in the clinical investigation plan agreed that no further follow up was necessary.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group 1</title>
          <description>At visit 1 the left upper palatal area was treated with lidocaine on a microneedle patch for three minutes and the right upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days after visit 1) the left upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Group 2</title>
          <description>At visit 1 the left upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes and the right upper palatal area was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days from visit 1) the left upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Group 3</title>
          <description>At visit 1 the left upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days from visit 1) the left upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes and the right upper palatal area was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
        <group group_id="E4">
          <title>Treatment Group 4</title>
          <description>At visit 1 the left upper anterior buccal sulcus was treated with lidocaine on a patch with no microneedles for three minutes and the right upper anterior buccal sulcus was treated with lidocaine on a microneedle patch for three minutes. Tests 1, 2 and 3 were then performed on both sites.
At visit 2 (2 weeks +/- 3 days after visit 1) the left upper palatal area was treated with lidocaine on a microneedle patch for three minutes and the right upper palatal area was treated with lidocaine on a patch with no microneedles for three minutes. Tests 1, 2 and 3 were then performed on both sites.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jemma Burridge, Clinical Project Manager</name_or_title>
      <organization>Innoture Ltd</organization>
      <phone>+44 (0)7799 902476</phone>
      <email>jburridge@innoture.co</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

